|
🐜
|
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
12 auth.
D. Reid,
J. Devogelaer,
K. Saag,
C. Roux,
C. Lau,
J. Reginster,
...
P. Papanastasiou,
A. Ferreira,
F. Hartl,
T. Fashola,
P. Mesenbrink,
P. Sambrook
|
8 |
2009 |
8
🐜
|
|
🐜
|
Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate
15 auth.
D. Hosking,
K. Lyles,
Jacques P. Brown,
W. Fraser,
P. Miller,
M. Curiel,
J. Devogelaer,
M. Hooper,
Guoqin Su,
K. Zelenakas,
...
Judy Pak,
T. Fashola,
Y. Saidi,
E. Eriksen,
I. Reid
|
7 |
2006 |
7
🐜
|
|
🐜
|
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis
16 auth.
J. Devogelaer,
Jacques P. Brown,
P. Burckhardt,
P. Meunier,
S. Goemaere,
K. Lippuner,
J. Body,
G. Samsioe,
D. Felsenberg,
T. Fashola,
...
Liuska Sanna,
C. Ortmann,
U. Trechsel,
J. Krasnow,
E. Eriksen,
P. Garnero
|
6 |
2007 |
6
🐜
|
|
🐢
|
Comparable Efficacy and Tolerability of Formoterol (Foradil®) Administered via a Novel Multi-Dose Dry Powder Inhaler (Certihaler™) or the Aerolizer® Dry Powder Inhaler in Patients with Persistent Asthma
9 auth.
R. Dahl,
J. Creemers,
J. V. van Noord,
A. Sips,
G. Della Cioppa,
M. Thomson,
...
K. Andriano,
J. Kottakis,
T. Fashola
|
4 |
2004 |
4
🐢
|
|
🐜
|
Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
9 auth.
A. Chuchalin,
A. Manjra,
Nadezhda N. Rozinova,
O. Skopková,
G. Cioppa,
D. Till,
...
G. Kaiser,
T. Fashola,
J. Kottakis
|
3 |
2005 |
3
🐜
|
|
🐜
|
A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease
16 auth.
John Brown,
K. Lyles,
W. Fraser,
I. Reid,
D. Hosking,
J. Devogelaer,
C. Moniz,
M. Hooper,
Y. Saidi,
Guoqin Su,
...
Judy Pak,
James Davis,
T. Fashola,
J. Krasnow,
K. Zelenakas,
P. Miller
|
0 |
2006 |
0
🐜
|
|
🐜
|
Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis
16 auth.
J. Devogelaer,
P. Burckhardt,
P. Meunier,
J. Kaufman,
K. Lippuner,
J. Body,
G. Samsioe,
D. Felsenberg,
John Brown,
P. Garnero,
...
L. Sanna,
C. Ortmann,
J. Krasnow,
E. Eriksen,
T. Fashola,
U. Trechsel
|
0 |
2006 |
0
🐜
|
|
🐜
|
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (health outcomes and reduced incidence with zoledronic acid once yearly trial): A multicentre, double-blind, double-dummy, randomized controlled trial
12 auth.
D. Reid,
J. Devogelaer,
K. Saag,
C. Roux,
C. Lau,
J. Reginster,
...
P. Papanastasiou,
A. Ferreira,
F. Hartl,
T. Fashola,
P. Mesenbrink,
P. Sambrook
|
0 |
2009 |
0
🐜
|
|
🐜
|
Effect of Zoledronic Acid (Single 5-mg Infusion) on Lumbar Spine Bone Mineral Density Versus Oral Risedronate (5 mg/day) Over 1 Year in Subgroups of Patients Receiving Glucocorticoid Therapy.
12 auth.
C. Roux,
J. Devogelaer,
D. Reid,
K. Saag,
C. Lau,
J. Reginster,
...
P. Papanastasiou,
A. Ferreira,
F. Hartl,
T. Fashola,
P. Mesenbrink,
P. Sambrook
|
0 |
2008 |
0
🐜
|
